An engineered virus shows potential as an immune therapy in glioblastoma

NATURE（2023）

引用 0|浏览6

暂无评分

摘要

Therapies for aggressive, recurrent glioblastomas are sorely needed but frequently fail in trials. A first-in-human trial of CAN-3110, an engineered herpes simplex virus 1 (HSV1), shows that it is safe and seems to extend survival and stimulate immune responses - particularly in people with antibodies to HSV1.

查看译文

关键词

Cancer, Drug discovery, Brain

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要